MOLOGEN AG capital increase: Proceeds of 22 million EUR

As part of the current capital increase MOLOGEN AG has achieved gross proceeds of 22 million EUR. Overall, 2,589,819 new shares have been placed at an issue price of 8.50 EUR. Existing investors contributed in a significant amount to the capital increase. In addition, subscriptions for shares by national and international institutional investors supplemented the order book. The funds are to be primarily used for further expansion of the product pipeline.

The Management and Supervisory Board of the company will file the implementation of the capital increase for entry in the German Commercial Register immediately. The delivery of the new shares is expected to take place one banking day after the admission of the new shares to trading on the Regulated Market of the Frankfurt Stock Exchange with additional post-admission obligations (Prime Standard), i.e. on July 16, 2012.

The quirin bank AG was responsible for overseeing the capital increase.

MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange (ISIN DE0006637200).

Memberships in associations:
BIO Deutschland e.V.  |  DECHEMA - Society for chemical technology and biotechnology e.V.  |  German industrial association of biotechnology (DIB)  |  Association for the Promotion of Science and Humanities in Germany  |  Association of German biotechnology companies (VBU)  |  Association of researching manufacturers of pharmaceuticals e.V. (VFA)  |  Association of the chemical industry e.V. (VCI)


Fabeckstraße 30
D-14195 Berlin
Tel: +49 (0) 30 - 84 17 88 - 0

Investor Relations
Jörg Petraß
[email protected]
Tel: +49 (0) 30 - 84 17 88 - 13

Press contact

Prof. Peter W. Hübner
[email protected]
Tel: +49 (0)  30 – 84 17 88 - 38

External Investor Relations

Kirchhoff Consult AG
Jens Hecht
[email protected]
Tel: +49 (0) 40 - 60 91 86 82

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.